Suggested remit: To appraise the clinical and cost effectiveness of teplizumab within its marketing authorisation for delaying the onset of type 1 diabetes in people aged 8 and over at risk of developing the condition.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6259

Provisional Schedule

Committee meeting 06 May 2025
Expected publication 16 July 2025

Project Team

Project lead Leena Issa

Email enquiries

External Assessment Group Kleijnen Systematic Reviews Ltd

Stakeholders

Companies sponsors Sanofi (Teplizumab)
Others Department of Health and Social Care
  NHS England
Patient carer groups Black Health Agency for Equality
  Diabetes Research and Wellness Foundation
  Diabetes UK
  Haemochromatosis UK
  InDependent Diabetes Trust
  JDRF
  Muslim Council of Britain
  Network of Sikh Organisations
  South Asian Health Foundation
  Specialised Healthcare Alliance
Professional groups Association for the Study of Obesity
  Association of British Clinical Diabetologists
  At the 4-Front
  British & Irish Hypertension Society
  British Association for Nursing in Cardiovascular Care
  British Association of Endocrine and Thyroid Surgeons
  British Geriatrics Society
  British Heart Foundation
  British Society for Paediatric Endocrinology & Diabetes
  National Metabolic Biochemistry Network
  Primary Care Diabetes Society
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society for Endocrinology
  TREND Diabetes
  UK Clinical Pharmacy Association
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies None
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health – Northern Ireland
  Diabetes UK Cymru
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Metabolic & Endocrine Disorders Group
  Cochrane UK
  Genomics England
  MRC Clinical Trials Unit
  National Institute for Health Research
  The Society for Research in Rehabilitation
  Wellcome Trust

Timeline

Key events during the development of the guidance:

Date Update
24 September 2024 Invitation to participate
03 July 2024 - 31 July 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6259
03 July 2024 In progress. Scoping commencing
23 February 2024 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during late September 2024 when we will write to you about how you can get involved.
14 March 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual